Acknowledgement
Supported by : National Research Foundation of Korea, National Evidence-based Healthcare Collaborating Agency of Korea
References
- Stefanini FR, Badaro E, Falabella P, et al. Anti-VEGF for the management of diabetic macular edema. J Immunol Res 2014;2014:632307.
- Cheung GCM, Lai TYY, Gomi F, et al. Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy. Asia Pac J Ophthalmol (Phila) 2017;6:527-34.
- Campa C, Alivernini G, Bolletta E, et al. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets 2016;17:328-36. https://doi.org/10.2174/1573399811666150615151324
- Lad EM, Hammill BG, Qualls LG, et al. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol 2014;158:537-43.e2. https://doi.org/10.1016/j.ajo.2014.05.014
- Jager RD, Mieler WF, Miller JW. et al. Age-related macular degeneration. N Engl J Med 2008;358:2606-17. https://doi.org/10.1056/NEJMra0801537
- Fogli S, Del Re M, Rofi E, et al. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond) 2018;32:1010-20. https://doi.org/10.1038/s41433-018-0021-7
- Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology 2018;125:708-24. https://doi.org/10.1016/j.ophtha.2017.11.019
- Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging 2017;12:1313-30. https://doi.org/10.2147/CIA.S143508
- Ashraf M, Souka AAR. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye (Lond) 2017;31:1523-36. https://doi.org/10.1038/eye.2017.81
- Villegas VM, Aranguren LA, Kovach JL, et al. Current advances in the treatment of neovascular age-related macular degeneration. Expert Opin Drug Deliv 2017;14:273-82. https://doi.org/10.1080/17425247.2016.1213240
- Zhang Y, Chioreso C, Schweizer ML, Abramoff MD. Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies. Invest Ophthalmol Vis Sci 2017;58:5616-27.
- Gemenetzi M, Patel PJ. A systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-related macular degeneration. Ophthalmol Ther 2017;6:79-92. https://doi.org/10.1007/s40123-017-0087-5
- La TY, Cho E, Kim EC, et al. Prevalence and risk factors for age-related macular degeneration: Korean National Health and Nutrition Examination Survey 2008-2011. Curr Eye Res 2014;39:1232-9. https://doi.org/10.3109/02713683.2014.907431
- Lorence DP, Spink A. Regional variation in medical systems data: influences on upcoding. J Med Syst 2002;26:369-81. https://doi.org/10.1023/A:1016405214914
- Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 2009;26:295-320. https://doi.org/10.2165/00002512-200926040-00002